Skip to content
OpenCapital
Get started
Travere Therapeutics, Inc. logo

Travere Therapeutics, Inc. (TVTX) Q1 2026 Earnings

TVTX·Reported May 4, 2026·After market close

Travere Therapeutics, Inc. reported Q1 2026 revenue of $127.2M (+55.6% YoY), missed analyst consensus of $136.2M by $9.0M. Diluted EPS came in at $-0.39 (+17.0% YoY), missed the $-0.30 consensus by $0.09.

Revenue
$127.2Mmissed by $9.0M
Consensus: $136.2M
Diluted EPS
$-0.39missed by $0.09
Consensus: $-0.30
SEC

SEC Filings

Earnings release8-K · 0001438533-26-000041
Quarterly report10-Q · 0001438533-26-000042

Financial Snapshot

Trailing eight quarters through Q1 2026

View all metrics

Q1 2026 Earnings FAQ

Common questions about Travere Therapeutics, Inc.'s Q1 2026 earnings report.

Travere Therapeutics, Inc. (TVTX) reported Q1 2026 earnings on May 4, 2026 after market close.

Travere Therapeutics, Inc. reported revenue of $127.2M and diluted EPS of $-0.39 for Q1 2026.

Revenue missed the consensus estimate of $136.2M by $9.0M. EPS missed the consensus estimate of $-0.30 by $0.09.

Compared to the same quarter a year prior, revenue grew 55.6% from $81.7M a year earlier and diluted EPS grew 17.0% from $-0.47.

You can read the 8-K earnings release (0001438533-26-000041) and the 10-Q periodic report (0001438533-26-000042) directly on SEC EDGAR. The filing index links above go to sec.gov.